Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Dec 17, 2021 10:19am
121 Views
Post# 34240343

RE:At least give us news about no news ...

RE:At least give us news about no news ...They have mentioned that we may not hear anything until early next year on the phase 1a results, so from their perspective, they likely think they have themselves covered on that. But I agree, the communications could be so much better. There are really easy, simple things that could be communicated that would help frame investor expectations appropriately and reduce hostility toward management. I really do not know why they don't sort that out better. Even if they communicated that they do not know themselves about certain items we speculate about here would be better than the hesitant and inconsistent communications strategy they currently tend to employ. But they probably do not want to let on that they themselves are not totally sure about issues we are all interested in. So we are left to read the tea leaves that are available, which often leads to less than perfect conclusions.  


longterm56 wrote: If you said you will announce something "by the end of the year", and then due to unforseen circumstances you find that you cannot keep that commitment, isn't it common courtesy to mention that you have a forced change of plans? 

I am simply astounded by the lack of communciation from this company.

  -LT


<< Previous
Bullboard Posts
Next >>